Team:NTU Taida/Circuit2
From 2014.igem.org
(Difference between revisions)
(Created page with "{{:Team:NTU_Taida/template/header}} {{:Team:NTU_Taida/template/css/bootstrap}} <html lang="en"> <head> <meta charset="utf-8"> <meta http-equiv="X-UA-Compatible" conten...") |
|||
Line 10: | Line 10: | ||
<!-- Bootstrap --> | <!-- Bootstrap --> | ||
+ | |||
<link href='http://fonts.googleapis.com/css?family=Snippet|Cabin+Sketch:400,700|Flamenco|Shadows+Into+Light|Shadows+Into+Light+Two|Julius+Sans+One|Kranky|Megrim&subset=latin,latin-ext' rel='stylesheet' type='text/css'> | <link href='http://fonts.googleapis.com/css?family=Snippet|Cabin+Sketch:400,700|Flamenco|Shadows+Into+Light|Shadows+Into+Light+Two|Julius+Sans+One|Kranky|Megrim&subset=latin,latin-ext' rel='stylesheet' type='text/css'> | ||
<!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries --> | <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries --> | ||
Line 18: | Line 19: | ||
<![endif]--> | <![endif]--> | ||
</head> | </head> | ||
- | <body> | + | <body id="top"> |
- | <nav class="navbar navbar-default navbar-fixed-top" role="navigation"> | + | <nav class="navbar navbar-default navbar-fixed-top" role="navigation" style="padding-top:20px"> |
<div class="container-fluid"> | <div class="container-fluid"> | ||
<!-- Brand and toggle get grouped for better mobile display --> | <!-- Brand and toggle get grouped for better mobile display --> | ||
Line 29: | Line 30: | ||
<span class="icon-bar"></span> | <span class="icon-bar"></span> | ||
</button> | </button> | ||
- | <a href=" | + | <a href="https://2014.igem.org/Team:NTU_Taida"><img id="logo" height="50" src="https://static.igem.org/mediawiki/2014/1/19/NTU_Taida_logo.jpg"></a> |
</div> | </div> | ||
Line 35: | Line 36: | ||
<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1"> | <div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1"> | ||
<ul class="nav navbar-nav"> | <ul class="nav navbar-nav"> | ||
- | <li class="active"><a href="TEAM | + | <li class="active"><a href="TEAM">TEAM</a></li> |
Line 41: | Line 42: | ||
<a href="#" class="dropdown-toggle" data-toggle="dropdown">PROJECT<span class="caret"></span></a> | <a href="#" class="dropdown-toggle" data-toggle="dropdown">PROJECT<span class="caret"></span></a> | ||
<ul class="dropdown-menu" role="menu"> | <ul class="dropdown-menu" role="menu"> | ||
- | <li><a href="problem | + | <li><a href="problem">Problem (introduction)</a></li> |
- | <li><a href="PROJECT | + | <li><a href="PROJECT">Overview Mind Map</a></li> |
<li class="divider"></li> | <li class="divider"></li> | ||
- | <li><a href="Circuit1 | + | <li><a href="Circuit1">Fad System</a></li> |
<li class="divider"></li> | <li class="divider"></li> | ||
- | <li><a href="Circuit2 | + | <li><a href="Circuit2">Skin Whitening --- PKEK</a></li> |
<li class="divider"></li> | <li class="divider"></li> | ||
- | <li><a href="Circuit3 | + | <li><a href="Circuit3"> Corneum decomposition --- Keratinase</a></li> |
<li class="divider"></li> | <li class="divider"></li> | ||
- | <li><a href="Circuit4 | + | <li><a href="Circuit4">Fragrance</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
Line 60: | Line 61: | ||
<ul class="dropdown-menu" role="menu"> | <ul class="dropdown-menu" role="menu"> | ||
- | <li><a href="M1 | + | <li><a href="M1">Our Simulation Progress</a></li> |
<li class="divider"></li> | <li class="divider"></li> | ||
- | <li><a href="M2 | + | <li><a href="M2">Model 1</a></li> |
- | <li><a href="M3 | + | <li><a href="M3">Model 2</a></li> |
- | <li><a href="M4 | + | <li><a href="M4">Model 3</a></li> |
<li class="divider"></li> | <li class="divider"></li> | ||
- | <li><a href="M5 | + | <li><a href="M5">Curve fitting</a></li> |
<li class="divider"></li> | <li class="divider"></li> | ||
- | <li><a href="M6 | + | <li><a href="M6">Background knowledge</a></li> |
<li class="divider"></li> | <li class="divider"></li> | ||
- | <li><a href="M7 | + | <li><a href="M7">Reference</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
- | + | <li class="dropdown"> | |
- | + | <a href="SAFETY" >SAFETY</a> | |
- | <a href=" | + | </li> |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
<li class="dropdown"> | <li class="dropdown"> | ||
- | <a href="PARTS | + | <a href="PARTS" >PARTS</a> |
</li> | </li> | ||
<li class="dropdown"> | <li class="dropdown"> | ||
- | <a href="LOGBOOK | + | <a href="LOGBOOK" >LOGBOOK</a> |
</li> | </li> | ||
<li class="dropdown"> | <li class="dropdown"> | ||
- | <a href="HP1 | + | <a href="HP1" >HUMAN PRACTICE</a> |
</li> | </li> | ||
+ | |||
+ | <li class="dropdown"> | ||
+ | <a href="#" class="dropdown-toggle" data-toggle="dropdown">SPONSORS<span class="caret"></span></a> | ||
+ | <ul class="dropdown-menu" role="menu"> | ||
+ | <li><a href="Apex">ApexBio Biotech</a></li> | ||
+ | <li><a href="Lih">LihPao Life Science</a></li> | ||
+ | </ul> | ||
+ | </li> | ||
+ | |||
<li class="active"> | <li class="active"> | ||
- | <a href="https://2014.igem.org/Main_Page"><img src=" | + | <a href="https://2014.igem.org/Main_Page"><img src="https://static.igem.org/mediawiki/2014/6/6f/NTU_Taida_iGEM_logo.jpg" width=30px;> |
MAIN PAGE 2014 | MAIN PAGE 2014 | ||
</a> </li> | </a> </li> | ||
+ | |||
+ | <li class="active"> | ||
+ | <a href="https://www.facebook.com/NationalTaiwanUniversityiGEM?fref=ts"><img src="https://static.igem.org/mediawiki/2014/5/5a/NTU_Taida_Facebook.jpg" width=100px;> | ||
+ | </a></li> | ||
</ul> | </ul> | ||
Line 142: | Line 149: | ||
<div id="menuwrapper"> | <div id="menuwrapper"> | ||
<div id="menu"> | <div id="menu"> | ||
- | <a href=" | + | <a href="#inspiration" class="menuitem"><img src="images/Inspiration.jpg"></a> |
- | <a href=" | + | <a href="#synthetic" class="menuitem"><img src="images/synthetic%20peptide%20sequence.jpg"></a> |
- | <a href=" | + | <a href="#background" class="menuitem"><img src="images/backgroud%20knowledge.jpg"></a> |
- | <a href=" | + | <a href="#reference" class="menuitem"><img src="images/reference.jpg"></a> |
</div> | </div> | ||
Line 155: | Line 162: | ||
</div> | </div> | ||
- | <div class="container" style="width:1200px;line-height:4em;padding:200px;padding-top:100px;padding-right:100px" float="left"> | + | <div class="container" style="width:1200px;line-height:4em;padding:200px;padding-top:100px;padding-right:100px" float="left" id="inspiration"> |
- | <div><center><h2 style="background-color:#eeeeee">Skin Whitening ---PKEK</h2></center></div> | + | <div><center><h2 style="background-color:#eeeeee" >Skin Whitening ---PKEK</h2></center></div> |
<li class="boxF"><h4 style="color:#00A0E9">Inspiration :</h4></p> | <li class="boxF"><h4 style="color:#00A0E9">Inspiration :</h4></p> | ||
- | <h5 style="line-height:1.4em;font-size:110%;">< | + | <h5 style="line-height:1.4em;font-size:110%;"><strong>Uneven skin pigmentation</strong> is a significant cosmetic concern, and the identification of topically applicable molecules to address this issue is of general interest. One of the most often used skin lighteners is hydroquinone or the hydroquinone glycoside of arbutin. However, these compounds have a cytotoxic effect on melanocytes and have an irritating effect on the skin. There is thus an increasing need for improved active ingredients for the treatment of hyperpigmentation, but also for the purely cosmetic lightening of relatively large areas of pigmented skin that are entirely appropriate to the individual skin.</p> |
- | + | The tetrapeptide PKEK (Pro-Lys-Glu-Lys) is described in the patent application WO/2008/085494 and in WO/2009/068351. It has immunomodulatory properties and also anti-aging efficacy .</p> | |
- | + | According to researches, PKEK may be delivered upon topical application into human skin where they subsequently exert biological effects on skin cells, including epidermal keratinocytes and dermal fibroblasts effects . | |
- | + | </h5> | |
- | + | ||
</li> | </li> | ||
Line 182: | Line 188: | ||
CTG CTG TTT ACC CCG GTG ACC AAA GCG</p> | CTG CTG TTT ACC CCG GTG ACC AAA GCG</p> | ||
<h5 style="line-height:1.4em;font-size:110%;"> | <h5 style="line-height:1.4em;font-size:110%;"> | ||
- | Unlike others, we have our own way to synthesize the signal sequence.</p> | + | <strong>Unlike others</strong>, we have our own way to synthesize the signal sequence.</p> |
It’s common to order whole gene sequences to Biotech, but the cost is always shocking, and since the budget limitation, we strive to find our way out.</p> | It’s common to order whole gene sequences to Biotech, but the cost is always shocking, and since the budget limitation, we strive to find our way out.</p> | ||
Here is our strategy:</p> | Here is our strategy:</p> | ||
Line 191: | Line 197: | ||
<img src="images/Prefix.jpg"> | <img src="images/Prefix.jpg"> | ||
<h5 style="line-height:1.4em;font-size:110%;"><b>1.PelB (66mer)</b></p> | <h5 style="line-height:1.4em;font-size:110%;"><b>1.PelB (66mer)</b></p> | ||
- | GAATTC GCGGCCGC T | + | GAATTC GCGGCCGC T T<em style="background-color:yellow">CTAG ATG AAA TAT CTG CTG CCG ACC GCG GCG</em><em style="background-color:LightGreen"> GCG GGC CTG CTG CTG CTG GCG GCG CAG CCG GCG ATG GCG T A</em>CTAGT A GCGGCCG CTGCAG</p> |
- | CTTAAG CGCCGGCG A AGATC TAC TTT ATA GAC GAC GGC TGG CGC CGC CGC CGC GAC GAC GAC GAC CGC CGC GTC GGC CGC TAC CGC A TGATCA T CGCCGGC GACGTC</p> | + | CTTAAG CGCCGGCG A AGATC <em style="background-color:lightBlue">TAC TTT ATA GAC GAC GGC TGG CGC CGC CGC CGC GAC GAC</em><em style="background-color:Lightsalmon"> GAC GAC CGC CGC GTC GGC CGC TAC CGC</em> A TGATCA T CGCCGGC GACGTC</p> |
<h5 style="line-height:1.4em;font-size:110%;"><b>2.OmpA (63mer)</b> | <h5 style="line-height:1.4em;font-size:110%;"><b>2.OmpA (63mer)</b> | ||
</p> | </p> | ||
- | GAATTC GCGGCCGC T | + | GAATTC GCGGCCGC T T<em style="background-color:yellow">CTAG ATG AAA AAA ACC GCG ATT GCG ATT GCG</em><em style="background-color:LightGreen"> GTG GCG CTG GCG GGC TTT GCG ACC GTG GCG CAG GCG T A</em>CTAGT A GCGGCCG CTGCAG</p> |
- | CTTAAG CGCCGGCG A AGATC TAC TTT TTT TGG CGC TAA CGC TAA CGC CAC CGC GAC CGC CCG AAA CGC TGG CAC CGC GTC CGC A TGATCA T CGCCGGC GACGTC</p> | + | CTTAAG CGCCGGCG A AGATC <em style="background-color:lightBlue">TAC TTT TTT TGG CGC TAA CGC TAA CGC CAC CGC GAC CGC </em><em style="background-color:Lightsalmon">CCG AAA CGC TGG CAC CGC GTC CGC </em>A TGATCA T CGCCGGC GACGTC</p> |
<h5 style="line-height:1.4em;font-size:110%;"><b>3.PhoA (63mer)</b> | <h5 style="line-height:1.4em;font-size:110%;"><b>3.PhoA (63mer)</b> | ||
- | GAATTC GCGGCCGC T | + | GAATTC GCGGCCGC T T<em style="background-color:yellow">CTAG ATG AAA CAG AGC ACC ATT GCG CTG GCG</em> <em style="background-color:LightGreen">CTG CTG CCG CTG CTG TTT ACC CCG GTG ACC AAA GCG T A</em>CTAGT A GCGGCCG CTGCAG</p> |
- | CTTAAG CGCCGGCG A AGATC TAC TTT GTC TCG TGG TAA CGC GAC CGC GAC GAC GGC GAC GAC AAA TGG GGC CAC TGG TTT CGC A TGATCA T CGCCGGC GACGTC</p> | + | CTTAAG CGCCGGCG A AGATC <em style="background-color:lightBlue">TAC TTT GTC TCG TGG TAA CGC GAC CGC GAC GAC GGC GAC </em><em style="background-color:Lightsalmon">GAC AAA TGG GGC CAC TGG TTT CGC</em> A TGATCA T CGCCGGC GACGTC</p> |
+ | The yellow, green, blue and red part in pictures are primers we order from Biotech. The combination of these four sequences will produce the sticky ends of XbaI and SpeI. We ligase the yellow and blue part with green and red one respectively. Finally, we linked these two parts with plasmid backbones treated with Xbal and Spel. </p> | ||
+ | Moreover, we should notice the possibility of antisense considering the sticky ends of XbaI and SpeI will pair together. After all the ligation and transformation process, we should use colony PCR to pick up out correct colony. On PSB1C3, there are two sequence: V2F and VR, provide the primer binding site. Therefore, while choose V2F and VR to be primers, we could still see band on gel even there’s no insertion. | ||
+ | Our experiment design can intelligently solve this problem. We use one of our signal sequences to replace VR sequence, so the cases of antisense and without insert will not have result during electrophoresis.</p> | ||
+ | All signal sequences are cloned and ligated on pSB1C3 plasmid backbone, which can be applied broadly as biobricks. By doing so, we significantly lower the cost compared to directly synthesize the nucleic acid sequences. And it is suitable for shorter gene sequence. We think it worth referencing by other iGEM teams.</p> | ||
+ | |||
+ | |||
+ | <h5 style="line-height:1.4em;font-size:110%;"><b>PKEK sequence</b></p> | ||
+ | In gram-negative bacteria, different types of protein secretion systems have been described , and we decided to put PKEK sequence directly behind the signal sequence, because it has only 18 nucleic acids. | ||
+ | PKEK (18mer) | ||
+ | |||
+ | </p> | ||
+ | <em><strong>CGC AAA GAA AAA TAA TAA</strong></em></p> | ||
+ | |||
</div> | </div> | ||
</li> | </li> | ||
- | + | ||
- | + | ||
- | + | ||
<li class="boxG" style="line-height:2em" float="left"> | <li class="boxG" style="line-height:2em" float="left"> | ||
- | <h4 style="color:#00A0E9">Background Knowledge :</h4> | + | <h4 style="color:#00A0E9" id="background">Background Knowledge :</h4> |
- | <h5 style="line-height:1.4em;font-size:110%;">Regulation of skin pigmentation is a highly comp process that in addition to melanin-synthesizing melanocytes involves the production of pigmentation-inducing soluble factors by epidermal keratinocytes including proinflammatory cytokines such as IL-6, IL-8 as well as alpha-melanocyte-stimulating hormone (a-MSH) | + | <h5 style="line-height:1.4em;font-size:110%;"> |
+ | <strong>Regulation</strong> of skin pigmentation is a highly comp process that in addition to melanin-synthesizing melanocytes involves the production of pigmentation-inducing soluble factors by epidermal keratinocytes including proinflammatory cytokines such as IL-6, IL-8 as well as alpha-melanocyte-stimulating hormone (a-MSH). And previously shown that as a general principle specific tetrapeptides may be delivered upon topical application into human skin where they subsequently exert biological effects on skin cells, including epidermal keratinocytes and dermal fibroblasts, and significantly modulating skin pigmentation . Furthermore, PKEK was equally capable of reducing POMC in UV-irradiated keratinocytes and in skin. Thus, PKEK interferes with the keratinocyte to melanocyte signaling processes involved in skin pigmentation was shown to reduce tyrosinase expression in vivo . | ||
</li> | </li> | ||
<li class="boxG"> | <li class="boxG"> | ||
- | <h4 style="color:#00A0E9">Reference :</h4> | + | <h4 style="color:#00A0E9" id="reference">Reference :</h4> |
+ | <h5 style="line-height:1.4em;font-size:110%;"> | ||
+ | Modulation of skin pigmentation by the tetrapeptide PKEK: in vitro and in vivo evidence for skin whitening effects | ||
+ | DOI:10.1111/j.1600-0625.2011.01415.x</p> | ||
+ | fadD deletion and fadL overexpression in Escherichia coli | ||
+ | increase hydroxy long-chain fatty acid productivity Appl Microbiol Biotechnol | ||
+ | DOI 10.1007/s00253-014-5974-2</h5> | ||
+ | </li> | ||
+ | <li class="boxG"> | ||
+ | <h4 style="color:#00A0E9"><a href="#top">Top</a></p></h4> | ||
</li> | </li> | ||
- | |||
</div> | </div> |
Revision as of 21:18, 17 October 2014